End-of-Life Care for Elderly Patients with Gynecologic Cancer

  • Lois M. RamondettaEmail author
  • Maxine Grace de la Cruz
  • EdenMae C. Rodriguez


In general, the survival outlook for gynecologic cancer patients with advanced disease is poor. Moreover, compared with younger women, older women often present with more advanced gynecological malignancies and are more likely to die from the disease. Symptom management is the most important aspect of care for a patient with advanced disease. The issues involved in providing care directed at excellent symptom management and patient QOL are complex and numerous for elderly gynecologic cancer patients. In this chapter, we discuss some of the end-of-life issues specific to this population as well as issues found more commonly in this population with gynecological cancer and other types of cancer.

This chapter addresses four specific areas of end-of-life supportive care and management strategies for elderly patients with gynecological cancer:
  1. 1.

    Gastrointestinal obstructions, fistula, ascites, and effusions at end of life

  2. 2.

    Pain management issues in elderly patients

  3. 3.

    Fatigue, anorexia, anxiety, and depression

  4. 4.

    Existential issues: dignity, independence, cognition, and attainment of goals



Cancer-related symptoms Pain control Bowel obstruction Psychological issues End-of-life care 


  1. 1.
    WHO. Cancer. World Health Organization; 2012 [cited 2012]; Available from:
  2. 2.
    Yancik R. Population aging and cancer: a cross-national concern. Cancer J. 2005;11:437–41.PubMedCrossRefGoogle Scholar
  3. 3.
    Extermann M, Aapro MS, Bernabe DG, Cohen HJ, Droz JP, Lichtman S, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55(3):241–52.PubMedCrossRefGoogle Scholar
  4. 4.
    Solomon DH. Geriatric assessment: methods for clinical decision making. JAMA. 1988;259(16):2450–2.PubMedCrossRefGoogle Scholar
  5. 5.
    Fried LP, Guralnik JM. Disability in older adults: evidence regarding significance, etiology, and risk. J Am Geriatr Soc. 1997;45(1):92–100.PubMedGoogle Scholar
  6. 6.
    Cesari M, Onder G, Russo A, Zamboni V, Barillaro C, Ferrucci L, et al. Comorbidity and physical function: results from the aging and longevity study in the Sirente geographic area (ilSIRENTE study). Gerontology. 2006;52(1):24–32.PubMedCrossRefGoogle Scholar
  7. 7.
    Balducci L, Colloca G, Cesari M, Gambassi G. Assessment and treatment of elderly patients with cancer. Surg Oncol. 2010;19(3):117–23.PubMedCrossRefGoogle Scholar
  8. 8.
    Inouye SK, Studenski S, Tinetti ME, Kuchel GA. Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. J Am Geriatr Soc. 2007;55(5):780–91.PubMedCrossRefGoogle Scholar
  9. 9.
    Mercadante S, Spoldi E, Caraceni A. Octreotide in relieving gastrointestinal symptoms due to bowel obstruction. Palliat Med. 1993;7:295–9.PubMedGoogle Scholar
  10. 10.
    Khoo D, Riley J, Waxman J. Control of emesis in bowel obstruction in terminally ill patients. Lancet. 1992;339:375–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Mangili G, Aletti G, Frigerio L, Franchi M, Panacci N, Vigano R, et al. Palliative care for intestinal obstruction in recurrent ovarian cancer: a multivariate analysis. Int J Gynecol Cancer. 2005;15(5):830–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Ripamonti C, Mercadante S, Groff L. Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective, randomized trial. J Pain Manage. 2000;19:23–34.CrossRefGoogle Scholar
  13. 13.
    Mercadante S, Maddaloni S. Octreotide in the management of inoperable gastrointestinal obstruction in terminal cancer patients. J Pain Symptom Manage. 1992;7(8):496–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Mangili G, Franchi M, Mariani A. Octreotide in the management of bowel obstruction in terminal ovarian cancer. Gynecol Oncol. 1996;61:345–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Feuer DJ, Broadley KE. Systematic review and meta-analysis of corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancers. Systematic Review Steering Committee. Ann Oncol. 1999;10(9):1035–41.PubMedCrossRefGoogle Scholar
  16. 16.
    Tsahalina E, Woolas RP, Carter PG, Chan F, Gore ME, Blake PM, et al. Gastrostomy tubes in patients with recurrent gynaecological cancer and intestinal obstruction. Br J Obstet Gynaecol. 1999;106(9):964–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Van Ooijen B, Van der Burg ME. Surgical treatment or gastric drainage only for intestinal obstruction in patients with carcinoma of the ovary or peritoneal carcinomatosis of other origin. Surg Gynecol Obstet. 1993;176:469–74.PubMedGoogle Scholar
  18. 18.
    Steadman K, Franks A. A woman with malignant bowel obstruction who did not want to die with tubes. Lancet. 1996;347:944.PubMedCrossRefGoogle Scholar
  19. 19.
    Sharkey JR. The interrelationship of nutritional risk factors, indicators of nutritional risk, and severity of disability among home-delivered meal participants. Gerontologist. 2002;42(3):373–80.PubMedCrossRefGoogle Scholar
  20. 20.
    Moynihan T, Kelly DG, Fisch MJ. To feed or not to feed: is that the right question? J Clin Oncol. 2005;23(25):6256–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Giantonio BJ. Bowel perforation and fistula formation in colorectal cancer patients treated on Eastern Cooperative Oncology Group (ECOG) studies E2200 and E3200. ASCO # 30172004.Google Scholar
  22. 22.
    Piso P, Dahlke MH, Loss M, Schlitt HJ. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg Oncol. 2004;2:21.PubMedCrossRefGoogle Scholar
  23. 23.
    Chamberlain RS, Kaufman HL, Danforth DN. Enterocutaneous fistula in cancer patients: etiology, management, outcome, and impact on further treatment. Am Surg. 1998;64(12):1204–11.PubMedGoogle Scholar
  24. 24.
    Riley J, Fallon MT. Octreotide in terminal malignant obstruction of the gastrointestinal tract. Eur J Palliat Care. 1994;1(1):20–2.Google Scholar
  25. 25.
    Hallfeldt K, Schmidbauer S, Trupka A. Laparoscopic loop colostomy for advanced ovarian cancer, rectal cancer, and rectovaginal fistulas. Gynecol Oncol. 2000;76(3):380–2.PubMedCrossRefGoogle Scholar
  26. 26.
    Bower M, Stein R, Evans TR, Hedley A, Pert P, Coombes RC. A double-blind study of the efficacy of metronidazole gel in the treatment of malodorous fungating tumours. Eur J Cancer. 1992;28A(4–5):888–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Seaman S. Management of malignant fungating wounds in advanced cancer. Semin Oncol Nurs. 2006;22:185–93.PubMedCrossRefGoogle Scholar
  28. 28.
    Lifshitz S. Ascites, pathophysiology and control measures. Int J Radiat Oncol Biol Phys. 1982;8(8):1423–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Rosenberg S, Courtney A, Nemcek Jr AA, Omary RA. Comparison of percutaneous management techniques for recurrent malignant ascites. J Vasc Interv Radiol. 2004;15(10):1129–31.PubMedCrossRefGoogle Scholar
  30. 30.
    Covey AM. Management of malignant pleural effusions and ascites. J Support Oncol. 2005;3:169–76.PubMedGoogle Scholar
  31. 31.
    Lee A, Lau TN, Yeong KY. Indwelling catheters for the management of malignant ascites. Support Care Cancer. 2000;8(6):493–9.PubMedGoogle Scholar
  32. 32.
    Macdonald R, Kirwan J, Roberts S. Ovarian cancer and ascites: a questionnaire on current management in the United Kingdom. J Palliat Med. 2006;9:1264–70.PubMedCrossRefGoogle Scholar
  33. 33.
    Cheung DK, Raaf JH. Selection of patients with malignant ascites for a peritoneovenous shunt. Cancer. 1982;50:1204–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Greenway B, Johnson PJ, Williams R. Control of malignant ascites with spironolactone. Br J Surg. 1982;69(8):441–2.PubMedCrossRefGoogle Scholar
  35. 35.
    Pockros PJ, Esrason KT, Nguyen C, Duque J, Woods S. Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics. Gastroenterology. 1992;103(4):1302–6.PubMedGoogle Scholar
  36. 36.
    van den Beuken MH, de Rijke JM, Kessels AG. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18:1437–49.CrossRefGoogle Scholar
  37. 37.
    McCarthy EP, Phillips RS, Zhong Z. Dying with cancer: patients’ function, symptoms, and care preferences as death approaches. J Am Geriatr Soc. 2000;48(5 Suppl):S110–21.PubMedGoogle Scholar
  38. 38.
    AGS. AGS panel on persistent pain in older adults: the management of persistent pain in older persons. J Am Geriatr Soc. 2002;50:S205–24.CrossRefGoogle Scholar
  39. 39.
    Hollenack KA, Cranmer KW, Zarowitz BJ, O’Shea T. The application of evidence-based principles of care in older persons: pain management. J Am Med Dir Assoc. 2006;7(8):512–22.CrossRefGoogle Scholar
  40. 40.
    Catananti C, Gambassi G. Pain assessment in the elderly. Surg Oncol. 2010;19(3):140–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Cohen MZ, Easley MK, Ellis C. Cancer pain management and the JCAHO’s pain standards. An institutional challenge. J Pain Symptom Manage. 2003;25:519–27.PubMedCrossRefGoogle Scholar
  42. 42.
    Gallagher P, O’Mahony D. STOPP (screening tool of older persons’ potentially inappropriate prescriptions): application to acutely ill elderly patients and comparison with beers’ criteria. Age Ageing. 2008;37(6):673–9.PubMedCrossRefGoogle Scholar
  43. 43.
    AGS. AGS panel on pharmacological management of persistent pain in older persons. The management of persistent pain in older persons. J Am Geriatr Soc. 2009;57:1331–46.CrossRefGoogle Scholar
  44. 44.
    Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol. 2001;19(9): 2542–54.PubMedGoogle Scholar
  45. 45.
    Solassol I, Caumette L, Bressolle F, Garcia F, Thezenas S, Astre C, et al. Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients. Oncol Rep. 2005;14(4):1029–36.PubMedGoogle Scholar
  46. 46.
    McPherson ML. Transdermal and parenteral fentanyl dosage calculations and conversions. Bethesda: American Society of Health-System Pharmacists; 2010.Google Scholar
  47. 47.
    Del Fabbro E, Elsayem A. Cancer pain management. Prevention and treatment of opioid side effects. In: Fish MJ, Burton AW, editors. Chicago: McGraw-Hill Medical; 2007.Google Scholar
  48. 48.
    Gloth 3rd FM. Pain management in older adults: prevention and treatment. J Am Geriatr Soc. 2001;49(2):188–99.PubMedCrossRefGoogle Scholar
  49. 49.
    Bradley S, Rose S, Lutgendorf S, Costanzo E, Anderson B. Quality of life and mental health in cervical and endometrial cancer survivors. Gynecol Oncol. 2006;100(3):479–86.PubMedCrossRefGoogle Scholar
  50. 50.
    van Lonkhuijzen L, Thomas G. Palliative radiotherapy for cervical carcinoma, a systematic review. Radiother Oncol. 2011;98(3):287–91.PubMedCrossRefGoogle Scholar
  51. 51.
    Cariati M, De Martini G, Pretolesi F, Roy MT. CT-guided superior hypogastric plexus block. J Comput Assist Tomogr. 2002;26(3):428–31.PubMedCrossRefGoogle Scholar
  52. 52.
    Rosenberg SK, Tewari R, Boswell MV, Thompson GA, Seftel AD. Superior hypogastric plexus block successfully treats severe penile pain after transurethral resection of the prostate. Reg Anesth Pain Med. 1998;23(6):618–20.PubMedGoogle Scholar
  53. 53.
    Plancarte R, de Leon-Casasola OA, El-Helaly M, Allende S, Lema MJ. Neurolytic superior hypogastric plexus block for chronic pelvic pain associated with cancer. Reg Anesth. 1997;22(6):562–8.PubMedGoogle Scholar
  54. 54.
    Morrow GR. Cancer-related fatigue: causes, consequences, and management. Oncologist. 2007;12 Suppl 1:1–3.PubMedCrossRefGoogle Scholar
  55. 55.
    Mock V, Atkinson A, Barsevick AM, Berger AM, Cimprich B, Eisenberger MA, et al. Cancer-related fatigue. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007;5(10):1054–78.PubMedGoogle Scholar
  56. 56.
    Cella D, Davis K, Breitbart W, Curt G. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol. 2001;19(14):3385–91.PubMedGoogle Scholar
  57. 57.
    Vogelzang NJ, Breitbart W, Cella D, Curt GA, Groopman JE, Horning SJ, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The fatigue coalition. Semin Hematol. 1997;34(3 Suppl 2):4–12.PubMedGoogle Scholar
  58. 58.
    Lawrence DP, Kupelnick B, Miller K, Devine D, Lau J. Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J Natl Cancer Inst Monogr. 2004;32:40–50.PubMedCrossRefGoogle Scholar
  59. 59.
    Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991;7(2):6–9.PubMedGoogle Scholar
  60. 60.
    Bruera E, Driver L, Barnes EA, Willey J, Shen L, Palmer JL, et al. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol. 2003;21(23):4439–43.PubMedCrossRefGoogle Scholar
  61. 61.
    Bruera E, Valero V, Driver L, Shen L, Willey J, Zhang T, et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol. 2006;24(13):2073–8.PubMedCrossRefGoogle Scholar
  62. 62.
    McMillan EM, Newhouse IJ. Exercise is an effective treatment modality for reducing cancer-related fatigue and improving physical capacity in cancer patients and survivors: a meta-analysis. Appl Physiol Nutr Metab. 2011;36(6):892–903.PubMedCrossRefGoogle Scholar
  63. 63.
    Liu L, Marler MR, Parker BA, Jones V, Johnson S, Cohen-Zion M, et al. The relationship between fatigue and light exposure during chemotherapy. Support Care Cancer. 2005;13(12):1010–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs. 2005;19(2):105–23.PubMedCrossRefGoogle Scholar
  65. 65.
    Cleeland CS, Bennett GJ, Dantzer R, Dougherty PM, Dunn AJ, Meyers CA, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer. 2003;97(11):2919–25.PubMedCrossRefGoogle Scholar
  66. 66.
    Del Fabbro E, Dalal S, Bruera E. Symptom control in palliative care – part II: cachexia/anorexia and fatigue. J Palliat Med. 2006;9(2):409–21.PubMedCrossRefGoogle Scholar
  67. 67.
    Corney RH, Crowther ME, Everett H, Howells A, Shepherd JH. Psychosexual dysfunction in women with gynaecological cancer following radical pelvic surgery. Br J Obstet Gynaecol. 1993;100(1):73–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Hipkins J, Whitworth M, Tarrier N, Jayson G. Social support, anxiety and depression after chemotherapy for ovarian cancer: a prospective study. Br J Health Psychol. 2004;9(Pt 4):569–81.PubMedCrossRefGoogle Scholar
  69. 69.
    Twillman RK, Manetto C. Concurrent psychotherapy and pharmacotherapy in the treatment of depression and anxiety in cancer patients. Psychooncology. 1998;7(4):285–90.PubMedCrossRefGoogle Scholar
  70. 70.
    Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163(22):2716–24.PubMedCrossRefGoogle Scholar
  71. 71.
    Roberts CS, Cox CE, Reintgen DS, Baile WF, Gibertini M. Influence of physician communication on newly diagnosed breast patients’ psychologic adjustment and decision-making. Cancer. 1994;74(1 Suppl):336–41.PubMedCrossRefGoogle Scholar
  72. 72.
    Baile WF, Buckman R, Lenzi R, Glober G, Beale EA, Kudelka AP. SPIKES – a six-step protocol for delivering bad news: application to the patient with cancer. Oncologist. 2000;5(4):302–11.PubMedCrossRefGoogle Scholar
  73. 73.
    Back AL, Arnold RM, Tulsky JA, Baile WF, Fryer-Edwards KA. Teaching communication skills to medical oncology fellows. J Clin Oncol. 2003;21(12):2433–6.PubMedCrossRefGoogle Scholar
  74. 74.
    Ptacek JT, Eberhardt TL. Breaking bad news. A review of the literature. JAMA. 1996;276(6):496–502.PubMedCrossRefGoogle Scholar
  75. 75.
    Haidet P, Hamel MB, Davis RB, Wenger N, Reding D, Kussin PS, et al. Outcomes, preferences for resuscitation, and physician-patient communication among patients with metastatic ­colorectal cancer. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Am J Med. 1998;105(3):222–9.PubMedCrossRefGoogle Scholar
  76. 76.
    Emanuel L. The health care directive: learning how to draft advance care documents. J Am Geriatr Soc. 1991;39(12):1221–8.PubMedGoogle Scholar
  77. 77.
    Ditto PH, Danks JH, Smucker WD, Bookwala J, Coppola KM, Dresser R, et al. Advance directives as acts of communication: a randomized controlled trial. Arch Intern Med. 2001;161(3):421–30.PubMedCrossRefGoogle Scholar
  78. 78.
    Smucker WD, Ditto PH, Moore KA, Druley JA, Danks JH, Townsend A. Elderly outpatients respond favorably to a physician-initiated advance directive discussion. J Am Board Fam Pract. 1993;6(5):473–82.PubMedGoogle Scholar
  79. 79.
    Hutcheson A. Hospice care in the United States. Prim Care. 2011;38(2):173–82, vii.PubMedCrossRefGoogle Scholar
  80. 80.
    Connor SR. U.S. hospice benefits. J Pain Symptom Manage. 2009;38(1):105–9.PubMedCrossRefGoogle Scholar
  81. 81.
    Virnig BA, Persily NA, Morgan RO, DeVito CA. Do Medicare HMOs and Medicare FFS differ in their use of the Medicare hospice benefit? Hosp J. 1999;14(1):1–12.PubMedGoogle Scholar
  82. 82.
    McCarthy EP, Burns RB, Ngo-Metzger Q, Davis RB, Phillips RS. Hospice use among Medicare managed care and fee-for-service patients dying with cancer. JAMA. 2003;289(17):2238–45.PubMedCrossRefGoogle Scholar
  83. 83.
    Bolmsjo I. Existential issues in palliative care – interviews with cancer patients. J Palliat Care. 2000;16(2):20–4.PubMedGoogle Scholar
  84. 84.
    LeMay K, Wilson KG. Treatment of existential distress in life threatening illness: a review of manualized interventions. Clin Psychol Rev. 2008;28(3):472–93.PubMedCrossRefGoogle Scholar
  85. 85.
    Chochinov HM, Kristjanson LJ, Breitbart W, McClement S, Hack TF, Hassard T, et al. Effect of dignity therapy on distress and end-of-life experience in terminally ill patients: a randomised controlled trial. Lancet Oncol. 2011;12(8):753–62.PubMedCrossRefGoogle Scholar
  86. 86.
    Bevans M, Sternberg EM. Caregiving burden, stress, and health effects among family caregivers of adult cancer patients. JAMA. 2012;307(4):398–403.PubMedCrossRefGoogle Scholar
  87. 87.
    Wenzel LB, Donnelly JP, Fowler JM, Habbal R, Taylor TH, Aziz N, et al. Resilience, reflection, and residual stress in ovarian cancer survivorship: a gynecologic oncology group study. Psychooncology. 2002;11(2):142–53.PubMedCrossRefGoogle Scholar
  88. 88.
    Wenzel L, DeAlba I, Habbal R, Kluhsman BC, Fairclough D, Krebs LU, et al. Quality of life in long-term cervical cancer survivors. Gynecol Oncol. 2005;97(2):310–7.PubMedCrossRefGoogle Scholar
  89. 89.
    Extermann M. Interaction between comorbidity and cancer. Cancer Control. 2007;14(1): 13–22.PubMedGoogle Scholar
  90. 90.
    Maas HA, Janssen-Heijnen ML, Olde Rikkert MG, Machteld Wymenga AN. Comprehensive geriatric assessment and its clinical impact in oncology. Eur J Cancer. 2007;43(15):2161–9.PubMedCrossRefGoogle Scholar
  91. 91.
    Carbonin P, Pahor M, Bernabei R, Sgadari A. Is age an independent risk factor of adverse drug reactions in hospitalized medical patients? J Am Geriatr Soc. 1991;39(11):1093–9.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • Lois M. Ramondetta
    • 1
    Email author
  • Maxine Grace de la Cruz
    • 2
  • EdenMae C. Rodriguez
    • 3
  1. 1.Department of Gynecologic Oncology and Reproductive Medicine, Unit 1362The University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of Palliative Care and Rehab MedicineThe University of Texas MD Anderson Cancer CenterHoustonUSA
  3. 3.Department of Pharmacy Clinical ProgramsThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations